Deal of the Year (£10m to £50m) - Shore Capital acted as Financial and Rule 3 Adviser to Styles & Wood Group plc
Life Science Analysis: RNA therapeutics are now a clinical reality
Shore Capital acted as Nominated Adviser & Sole Bookrunner on the IPO of Nucleus Financial Group
SEE ALL NEWS
Message from the Executive Chairman
Within our sector coverage Shore Capital follows industries and stocks from top to bottom. In this respect, we are distinctive in offering competitive and well established analysis in FTSE-100 stocks right down to AIM and FTSE Small-Cap equities.